On January 31, 2024, BioNTech SE announced that the FDA granted Fast Track designation for its drug BNT325/DB-1305, aimed at treating platinum-resistant ovarian cancer.
AI Assistant
BIONTECH SE
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.